- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03935555
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Phase 1b Study of PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Treated With Ruxolitinib
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Larkspur, California, United States, 94904
- Marin Cancer Care - Greenbrae (California Cancer Care A Medical Group, Inc. - Greenbrae)
-
Los Angeles, California, United States, 90095
- Ronald Reagan UCLA Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is willing and able to provide written informed consent before any study-specific procedures are performed.
- Subject is willing to comply with all study procedures and restrictions.
- Subject is ≥18 years of age.
- Subject has confirmed diagnosis of PMF, Post-PV MF, or Post-ET MF.
Subject has been receiving ruxolitinib therapy meeting the following criteria:
- Receiving ruxolitinib >3 months prior to enrollment.
- Stable dose for 8 weeks before starting therapy with PU-H71.
Subject with evidence of evaluable residual burden of disease following ruxolitinib monotherapy treatment, consisting of:
• Persistent or worsening disease-related symptoms, including but not limited to fatigue, pruritus, night sweats, early satiety, and other symptoms as determined by a Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) score of >12 points.
AND
• Documented splenomegaly of at least 5 cm below the costal margin as measured on inspiration by physical examination.
- Subject has an Eastern Cooperative Oncology Group performance status of 0 to 2.
Acceptable pre-study organ function during screening defined as:
- Absolute neutrophil count (ANC) ≥1000/µL.
- Platelet count ≥50,000/µL.
- Alanine aminotransferase or aspartate aminotransferase ≤2×upper limit of normal.
- Direct serum bilirubin ≤ 1.5×upper limit of normal.
- Creatinine clearance >50 mL/min/1.73 m2 based on the Cockcroft Gault equation.
If female and of childbearing potential (premenopausal and not surgically sterile), the subject:
- Must have a negative serum or urine pregnancy test at screening. The serum pregnancy test must be obtained prior to the first administration of PU-H71 (≤72 hours prior to dosing) in all premenopausal women and women <2 years after the onset of menopause.
- Must agree to use an acceptable method of effective contraception for the duration of the study and for 13 weeks after receiving the last dose of study treatment.
If male, the subject agrees to:
- Use an acceptable method of effective contraception for the duration of the study and for 13 weeks after receiving study treatment.
- Agrees to abstain from sperm donation for the duration of the study and for 13 weeks after receiving the last dose of study treatment
Exclusion Criteria:
- Subject has known active liver disease, including viral hepatitis or cirrhosis.
- Subject has known or suspected human immunodeficiency virus (HIV) or other active infections requiring acute or chronic treatment with systemic antibiotics. Conditions requiring topical antibiotics are acceptable.
- Subject has a QT interval corrected using Fridericia's formula (QTcF) >480 ms (corrected) in the screening or baseline ECG based on median value of ECG's obtained.
- Subject has left ventricular ejection fraction (LVEF) ≤50%, or below institution's lower limit of normal (whichever is lower), by echocardiogram or multigated acquisition (MUGA) scan.
- Subject has a history (or family history) of long QT syndrome.
- Subject has coronary artery disease with an ischemic event within 6 months prior to screening.
- Subject has a permanent cardiac pacemaker.
- Subject has history of a second primary malignancy within the past 2 years, except for the following (if appropriately treated and considered cured): Stage I endometrial, surgically treated cervical or prostate carcinoma, and non-melanoma skin cancer.
- Subject has significant uncontrolled medical condition within 6 months prior to screening, as determined by the Investigator.
- Subject has planned use of antineoplastic agents (chemotherapy or cytotoxic drugs), immunotherapy, experimental therapy, or biologic therapy for treatment of MPN with the exception of ruxolitinib.
- Subject uses systemic corticosteroids (ie, prednisone >12.5 mg/day or dexamethasone >2 mg/day) within 2 weeks prior to Cycle 1 Day 1.
- Subject has planned or current use of strong CYP3A4/5, CYP2D6, or CYP2C19 inhibitors or inducers within 1 week or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
- Subject has planned or current use of medications that carry a risk for Torsades de Pointes within 1 week or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
- Subject has planned or current use of herbal preparations/medications at least 7 days prior to Cycle 1 Day 1.
- Subject has previously received PU-H71.
- Subject has concurrent participation in any interventional studies (except PU-H71-Positive Emission Tomography (PET) Scan Studies) within 14 days or 5 half-lives (whichever duration is longer) of Cycle 1 Day 1.
- Subject has uncontrolled diabetes mellitus, in the judgment of the Investigator.
- Subject has any other condition or laboratory abnormality or receives any other treatment(s) that may increase the risk associated with study participation or may interfere with the interpretation of study results in the judgment of the Investigator.
- Subject has an active ocular condition that in the opinion of the Investigator, may alter visual acuity during the course of the study (ie, ocular inflammatory disease, etc.) or a history or anticipation of major ocular surgery (including cataract extraction, intraocular surgery, etc.) during the study.
- Women who are pregnant or breastfeeding or plan to become pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oral - 50mg
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
|
PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
|
Experimental: Oral -100 mg
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
|
PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
|
Experimental: Oral - 200 mg
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
|
PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
|
Experimental: Oral - 300 mg
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
|
PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Time Frame: 24 weeks
|
Determine the human exposure PK including Cmax
|
24 weeks
|
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Time Frame: 24 weeks
|
Determine the human exposure PK including Tmax
|
24 weeks
|
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Time Frame: 24 weeks
|
Determine the human exposure PK including AUC0-t
|
24 weeks
|
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Time Frame: 24 weeks
|
Determine the human exposure PK including AUC0-inf
|
24 weeks
|
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Time Frame: 24 weeks
|
Determine the human exposure PK including CL
|
24 weeks
|
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Time Frame: 24 weeks
|
Determine the human exposure PK including t1/2
|
24 weeks
|
Assess Safety and Tolerability of PU-H71
Time Frame: 24 weeks
|
Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in physical examinations
|
24 weeks
|
Assess Safety and Tolerability of PU-H71
Time Frame: 24 weeks
|
Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in electrocardiograms (ECGs)
|
24 weeks
|
Assess Safety and Tolerability of PU-H71
Time Frame: 24 weeks
|
Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in vital signs
|
24 weeks
|
Assess Safety and Tolerability of PU-H71
Time Frame: 24 weeks
|
Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in clinical laboratory evaluations
|
24 weeks
|
Assess treatment response of PU H71
Time Frame: 24 weeks
|
Treatment response in myelofibrosis (MF) is to be evaluated using the revised International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
|
24 weeks
|
Assess treatment response of PU H71
Time Frame: 24 weeks
|
Treatment response in myelofibrosis (MF) is to be evaluated using the revised European LeukemiaNet (ELN) response criteria.
|
24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Michael Silverman, M.D., Samus Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Bone Marrow Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Myeloproliferative Disorders
- Blood Coagulation Disorders
- Blood Platelet Disorders
- Bone Marrow Neoplasms
- Hematologic Neoplasms
- Primary Myelofibrosis
- Thrombocytosis
- Thrombocythemia, Essential
- Polycythemia Vera
- Polycythemia
- Antineoplastic Agents
- 9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-
Other Study ID Numbers
- PU-H71-01-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Myelofibrosis (PMF)
-
Novartis PharmaceuticalsCompletedPrimary Myelofibrosis (PMF) | Post Polycythaemia Myelofibrosis (PPV MF) | Post Essential Thrombocythaemia Myelofibrosis (PET-MF)United Kingdom
-
University of UlmActive, not recruitingPrimary Myelofibrosis | Secondary Myelofibrosis | Post-PV MF | PMF | SMF | Post-ET MFGermany
-
Kartos Therapeutics, Inc.RecruitingPrimary Myelofibrosis (PMF) | Post-Polycythemia Vera Myelofibrosis (Post-PV-MF) | Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)United States, Mexico, Bulgaria, Poland, Russian Federation, Belarus, Georgia, South Africa, Ukraine
-
Imago BioSciences, Inc., a subsidiary of Merck...CompletedMyelofibrosis | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (PPV-MF) | Post-essential Thrombocythemia Myelofibrosis (PET-MF)Germany, United States, Australia, Italy, United Kingdom
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompletedPrimary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis(Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)China
-
Sierra Oncology LLC - a GSK companyCompletedPrimary Myelofibrosis (PMF) | Post-polycythemia Vera (Post-PV) Myelofibrosis | Postessential Thrombocythemia (Post-ET) MyelofibrosisUnited States, Canada
-
GlaxoSmithKlineActive, not recruitingNeoplasms | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)United States, Hungary, Israel, Spain, Taiwan, France, Australia, Germany, Belgium, Canada, Singapore, Korea, Republic of, United Kingdom, Denmark, Austria, Romania, Italy, Bulgaria, Poland, Netherlands
-
AstraZenecaUniversity of Texas; Gustave Roussy, Cancer Campus, Grand Paris; New York City...CompletedPrimary Myelofibrosis (PMF) | Post-Polycythaemia Vera | Essential Thrombocythaemia MyelofibrosisUnited States, France
-
Icahn School of Medicine at Mount SinaiDompé Farmaceutici S.p.ARecruitingMyelofibrosis (PMF) | Post Essential Thrombocythemia Myelofibrosis (ET-MF) | Post Polycythemia Vera Related Myelofibrosis (PV-MF)United States
-
Sierra Oncology, Inc.CompletedPrimary Myelofibrosis (PMF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Post-polycythemia Vera (Post-PV)United States, Canada, France, Italy, Germany, Spain, Israel, United Kingdom
Clinical Trials on PU-H71
-
Memorial Sloan Kettering Cancer CenterCompletedLymphoma | Metastatic Solid Tumor | Myeloproliferative Neoplasms (MPN)United States
-
National Cancer Institute (NCI)TerminatedLymphoma | Solid TumorsUnited States
-
Samus Therapeutics, Inc.TerminatedPrimary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisUnited States
-
The Hong Kong Polytechnic UniversityCompletedPrevention of Pressure UlcersChina
-
PU sensor ABScandinavian CROCompleted
-
Samus Therapeutics, Inc.TerminatedAlzheimer's DiseaseUnited States
-
Staffordshire UniversityIndia Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes HospitalsCompletedDiabetes Complications | Diabetic NeuropathiesIndia
-
University GhentCare of Sweden ABCompletedPressure Ulcer | Pressure Injury | Pressure Ulcer, Buttock | Pressure SoreBelgium
-
Samus Therapeutics, Inc.Memorial Sloan Kettering Cancer Center; Weill Medical College of Cornell University and other collaboratorsTerminatedLymphoma | Alzheimer Disease | Myeloma | Solid MalignancyUnited States
-
Samus Therapeutics, Inc.WithdrawnAmyotrophic Lateral Sclerosis (ALS)